CorMedix price target lowered to $12 from $14 at Truist

Truist lowered the firm’s price target on CorMedix to $12 from $14 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in BioPharma. The firm looks forward to more visibility on inpatient launch figures beginning in Q2, though outpatient launch won’t show up until Q3 results, the analyst tells investors in a research note. Truist remains positive on the stock however and expects Defencath to become the standard of care across all dialysis procedures.